NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 2,572 Shares

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 2,572 shares of NeuroPace stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $6.35, for a total value of $16,332.20. Following the transaction, the insider now owns 5,525,905 shares of the company’s stock, valued at approximately $35,089,496.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The shares were sold at an average price of $6.57, for a total transaction of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total transaction of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total transaction of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Stock Up 1.3 %

Shares of NPCE opened at $6.47 on Friday. The stock has a 50 day moving average price of $7.05 and a 200 day moving average price of $8.41. NeuroPace, Inc. has a one year low of $5.73 and a one year high of $18.15. The company has a debt-to-equity ratio of 5.97, a quick ratio of 5.47 and a current ratio of 6.37. The stock has a market capitalization of $186.13 million, a price-to-earnings ratio of -5.44 and a beta of 1.78.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $19.26 million during the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.36) earnings per share. Equities research analysts forecast that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NPCE has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price objective on shares of NeuroPace in a report on Wednesday, August 14th. Morgan Stanley dropped their price target on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Wells Fargo & Company cut their price target on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Institutional Trading of NeuroPace

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC boosted its holdings in shares of NeuroPace by 13.3% during the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares during the last quarter. XTX Topco Ltd boosted its stake in NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after buying an additional 8,643 shares during the last quarter. Acadian Asset Management LLC grew its holdings in NeuroPace by 46.0% in the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after buying an additional 21,703 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of NeuroPace in the 2nd quarter worth $111,000. Finally, Financial Advocates Investment Management raised its holdings in shares of NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after acquiring an additional 5,000 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.